Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
VMF
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Ac-2nal-4cpa-3pal-ser-4aph(hydroorotyl)-4aph(carbamoyl)-leu-ilys-pro-ala-nh2
2. Acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ilys-prolyl-alaninamide
3. Degarelix
4. Fe 200486
5. Fe-200486
6. Fe200486
7. Firmagon
8. Gonax
9. Uglypeptide1
1. 934016-19-0
2. Gonax
3. Firmagon
4. Ext215f4zu
5. Degarelix (as Acetate)
6. Degarelix Acetate Hydrate
7. Fe-200486
8. Degarelix Acetate (jan)
9. N-acetyl-3-(2-naphthalenyl)-d-alanyl-4-chloro-d-phenylalanyl-3-(3-pyridinyl)-d-alanyl-l-seryl-4-[[[(4s)-hexahydro-2,6-dioxo-4-pyrimidinyl]carbonyl]amino]-l-phenylalanyl-4-[(aminocarbonyl)amino]-d-phenylalanyl-l-leucyl-n6-(1-methylethyl)-l-lysyl-l-prolyl-d-alaninamide,monoacetate
10. Asp3550
11. Fe200486
12. Unii-ext215f4zu
13. Fe200486 (free Base)
14. Firmagon (tn)
15. Degarelix Monoacetate
16. Chembl2028987
17. Degarelix Acetate Anhydrous
18. Dtxsid201027699
19. Asp-3550
20. Mfcd16879085
21. Degarelix Monoacetate Anhydrous
22. Degarelix (acetate) Pound>>fe 200486
23. Degarelix Acetate(214766-78-6 Free Base)
24. D09400
25. Q27277419
26. D-alaninamide, N-acetyl-3-(naphtalen-2-yl)-d-alanyl-4-chloro-d-phenylalanyl-3-(pyridin-3-yl)-d-alanyl-l-seryl-4-((((4s)-2,6-dioxohexahydropyrimidin-4-yl)carbonyl)amino)-l-phenylalanyl-4-(carbamoylamino)-d-phenylalanyl-l-leucyl-n6-(1-methylethyl)-l-lysyl-l-prolyl-, Acetate (1:1)
Molecular Weight | 1692.3 g/mol |
---|---|
Molecular Formula | C84H107ClN18O18 |
Hydrogen Bond Donor Count | 18 |
Hydrogen Bond Acceptor Count | 20 |
Rotatable Bond Count | 41 |
Exact Mass | 1690.7699263 g/mol |
Monoisotopic Mass | 1690.7699263 g/mol |
Topological Polar Surface Area | 550 Ų |
Heavy Atom Count | 121 |
Formal Charge | 0 |
Complexity | 3420 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 11 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
FIRMAGON is a gonadotrophin releasing hormone (GnRH) antagonist indicated:
- for treatment of adult male patients with advanced hormone-dependent prostate cancer .
- for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.
- as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer .
L02BX02
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?